Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes—a randomized controlled trial
- 21 January 2011
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (5) , 439-445
Abstract
Aim: Endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are markers of endothelial injury and repair. We compared the effects of pioglitazone versus metformin on the circulating numbers of EMPs and EPCs in patients with newly diagnosed type 2 diabetes. Methods: This was a randomized, double‐blind, comparator‐controlled, 24‐week single‐centre trial conducted in a Teaching Hospital in Naples, Italy. One hundred and ten people with newly diagnosed type 2 diabetes who were never treated with antihyperglycaemic drugs and had haemoglobin A1c (HbA1c) levels between 7 and 10% were given pioglitazone hydrochloride (15–45 mg/day) (n = 55) or metformin (1000–2000 mg/day) (n = 55) as an active comparator. Absolute change from baseline to final visit in circulating EMPs and EPCs and their ratio were the main outcomes. Results: Baseline characteristics did not differ between the study groups. The decrease in circulating EMPs CD31+ [intergroup difference, −32 counts/µl (95% CI −51 to −9)] and the increase in EPCs CD34+/KDR+ [intergroup difference, 33 cells/10 6 events (95% CI 13 to 55)] were greater with pioglitazone versus metformin. EMPs/EPCs ratio was reduced with pioglitazone and unchanged with metformin [difference, −1.5 (95% CI −2.6 to −0.5), p < 0.001]. Participants assigned to pioglitazone gained more weight and experienced greater improvements in some coronary risk measures [high‐density lipoprotein (HDL)‐cholesterol, triglycerides, adiponectin and C‐reactive protein (CRP)] than did those assigned to metformin. Conclusion: Compared with metformin, pioglitazone treatment improved the imbalance between endothelial damage and repair capacity and led to more favourable changes in coronary risk factors in patients with newly diagnosed type 2 diabetes.Keywords
This publication has 29 references indexed in Scilit:
- Time Course and Mechanisms of Circulating Progenitor Cell Reduction in the Natural History of Type 2 DiabetesDiabetes Care, 2010
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competenceJournal of Cellular and Molecular Medicine, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Endothelial microparticles correlate with erectile dysfunction in diabetic menInternational Journal Of Impotence Research, 2006
- Endothelium-derived microparticles impair endothelial function in vitroAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- The clinical implications of endothelial dysfunctionJACC, 2003
- Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular StructuresCirculation, 2002
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998